PBDA Stock Chart & Stats
€2.20
€0.00(0.00%)
At close: 4:00 PM EDT
€2.20
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.36 - €2.66
Previous CloseN/A
Volume0.00
Average Volume (3M)51.00
Market Cap
€199.88M
Enterprise Value€160.20M
Total Cash (Recent Filing)€27.42M
Total Debt (Recent Filing)€9.21M
Price to Earnings (P/E)11.4
Beta1.11
Next Earnings
Nov 16, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.24
Shares Outstanding80,571,640
10 Day Avg. Volume0
30 Day Avg. Volume51
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.93
Price to Sales (P/S)2.68
P/FCF Ratio-10.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.70Price Target Upside386.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.16
Revenue Forecast (FY)€70.09M
Bulls Say, Bears Say
Bulls Say
Improved Profitability And MarginsThe shift to positive earnings and strong operating margins indicates materially improved economics for the current business. If product sales remain durable, this profitability can support internal funding for commercial expansion and pipeline development while reducing reliance on external capital.
Debt-free Balance Sheet And Positive Cash GenerationPositive operating and free cash flow, combined with $40.7M of liquidity and no outstanding debt or warrants, gives Protalix financial flexibility. This supports ongoing operations and clinical investment while reducing financing pressure during periods of revenue variability.
Elfabrio Commercial And Regulatory ExpansionGrowth in Elfabrio sales alongside additional geographic and dosing approvals strengthens the product’s commercial reach and convenience proposition. Broader access and less frequent dosing can support adoption and provide a durable foundation for recurring product revenue.
Bears Say
Partner Concentration And Non-recurring RevenueDependence on Chiesi purchasing patterns can make reported revenue uneven and reduce forecasting visibility. The $25M milestone also materially boosted H1 results but may not recur, meaning ongoing performance must increasingly be supported by repeat product sales rather than partner events.
PRX-115 Immunogenicity RiskThe observed anti-drug antibody rate creates a meaningful development risk for PRX-115 because immunogenicity may affect efficacy, tolerability, and the eventual dosing strategy. This could complicate advancement of the program and reduce the value of its pipeline opportunity.
Volatile And Potentially Less Durable Cash ConversionAlthough current cash generation is positive, the sharp year-over-year decline and history of negative cash flow show that conversion has not been consistently durable. Continued volatility could constrain self-funded investment and increase dependence on milestone timing or partner payments.
Protalix News
PBDA FAQ
What was Protalix Biotherapeutics’s price range in the past 12 months?
Protalix Biotherapeutics lowest stock price was €1.36 and its highest was €2.66 in the past 12 months.
What is Protalix Biotherapeutics’s market cap?
Protalix Biotherapeutics’s market cap is €199.88M.
When is Protalix Biotherapeutics’s upcoming earnings report date?
Protalix Biotherapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 32 days.
How were Protalix Biotherapeutics’s earnings last quarter?
Protalix Biotherapeutics released its earnings results on Aug 12, 2026. The company reported €0.045 earnings per share for the quarter, beating the consensus estimate of -€0.009 by €0.054.
Is Protalix Biotherapeutics overvalued?
According to Wall Street analysts Protalix Biotherapeutics’s price is currently Undervalued.
Does Protalix Biotherapeutics pay dividends?
Protalix Biotherapeutics does not currently pay dividends.
What is Protalix Biotherapeutics’s EPS estimate?
Protalix Biotherapeutics’s EPS estimate is -0.02.
How many shares outstanding does Protalix Biotherapeutics have?
Protalix Biotherapeutics has 80,571,640 shares outstanding.
What happened to Protalix Biotherapeutics’s price movement after its last earnings report?
Protalix Biotherapeutics reported an EPS of €0.045 in its last earnings report, beating expectations of -€0.009. Following the earnings report the stock price went up 7.637%.
Which hedge fund is a major shareholder of Protalix Biotherapeutics?
Currently, no hedge funds are holding shares in DE:PBDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Protalix Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€10.70 (386.45% Upside)
€10.70 (386.45% Upside)
Blogger Sentiment
Bearish
DE:PBDA Sentiment 100%
Sector Average 67%
Sector Average 67%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.24%
12-Months-Change
Fundamentals
Return on Equity
31.61%
Trailing 12-Months
Asset Growth
40.58%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Protalix Biotherapeutics
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
PBDA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented several strong operational and financial positives — double-digit quarterly revenue growth, a >100% year-to-date revenue increase, meaningful Q2 net income, strong Elfabrio commercial momentum with regulatory and patent tailwinds, a solid cash position and advancing pipeline (PRX-115 with topline expected H2 2027). Offsetting risks include quarter-to-quarter revenue lumpiness and partner concentration (Chiesi), a reliance on a one-time $25M milestone in H1, increased cost of revenues and taxes, and clinical uncertainties around immunogenicity and regimen selection for PRX-115. Overall, the positives — particularly the robust revenue growth, improved profitability and cash position — outweigh the noted risks, though sustainability and immunogenicity remain items to monitor.View all DE:PBDA earnings summariesPBDA Stock 12 Month Forecast
Average Price Target
€10.70
▲(386.45% Upside)
Technical Analysis
Coherus Biosciences
―
SELLAS Life Sciences Group
―
Protara Therapeutics
―
―
Innate Pharma
―